Insulin human is under clinical development by Oramed Pharmaceuticals and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Insulin human’s likelihood of approval (LoA) and phase transition for Type 2 Diabetes took place on 29 Aug 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Insulin human Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Insulin human overview
Insulin human (ORMD-0801) is under development for the treatment of NASH, type 1 diabetes and type 2 diabetes. The drug candidate is administered through oral route as a capsule. It is based on POD (Protein Oral Delivery) technology.
Oramed Pharmaceuticals overview
Oramed Pharmaceuticals (Oramed) is a pharmaceutical company that carries out research and development of novel pharmaceutical solutions, comprising an oral insulin capsule used for the treatment of people with diabetes and orally ingestible capsules for delivery of other polypeptides. It developed a novel proprietary platform technology, protein oral delivery (POD) to transform injectable treatments into oral therapies. The technology allows for the oral delivery of drugs and is administered only by injection. Its pipeline products are intended for the treatment of type 1 and type 2 diabetes. The company also focuses on the development of combination therapy of insulin and GLP-1 analogs for the management of type 2 diabetes. Oramed is headquartered in New York, the US.
Quick View Insulin human LOA Data
|Highest Development Stage|